Two Sigma Investments
SPRO icon

Two Sigma Investments’s Spero Therapeutics SPRO Stock Holding History

Two Sigma Investments’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.07M Buy
885,631
+513,061
+138% +$1.22M ﹤0.01% 2732
2025
Q4 		$868K Buy
372,570
+323,171
+654% +$750K ﹤0.01% 3025
2025
Q3 		$92.9K Buy
+49,399
New +$109K ﹤0.01% 3481
2023
Q4 		– Sell
-17,023
Closed -$20.6K – 3366
2023
Q3 		$20.6K Sell
17,023
-67,512
-80% -$93.5K ﹤0.01% 2870
2023
Q2 		$123K Buy
84,535
+52,435
+163% +$89.8K ﹤0.01% 2727
2023
Q1 		$46.5K Sell
32,100
-7,695
-19% -$12.9K ﹤0.01% 2768
2022
Q4 		$68.8K Buy
+39,795
New +$74.3K ﹤0.01% 2557
2022
Q3 		– Sell
-437,280
Closed -$324K – 2804
2022
Q2 		$324K Buy
437,280
+358,372
+454% +$1.04M ﹤0.01% 2002
2022
Q1 		$686K Buy
+78,908
New +$808K ﹤0.01% 1873
2021
Q1 		– Sell
-43,373
Closed -$841K – 4223
2020
Q4 		$841K Buy
+43,373
New +$676K ﹤0.01% 2134
2020
Q3 		– Sell
-28,150
Closed -$381K – 3518
2020
Q2 		$381K Buy
+28,150
New +$316K ﹤0.01% 2205
2020
Q1 		– Sell
-18,828
Closed -$181K – 3775
2019
Q4 		$181K Buy
+18,828
New +$203K ﹤0.01% 3443
2019
Q1 		– Sell
-27,454
Closed -$169K – 3439
2018
Q4 		$169K Buy
+27,454
New +$222K ﹤0.01% 2744

Other funds holding SPRO

GP
GSK plc London $599M AUM
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Two Sigma Investments's SPRO Position: Q1 2026 in Review

Two Sigma Investments increased its Spero Therapeutics (SPRO) stake by 138% in Q1 2026, buying an estimated $1.22M and bringing the position to 885,631 shares worth $2.07M. The position accounts for ﹤0.01% of the portfolio, ranked #2732.

Two Sigma Investments first reported a position in SPRO in Q4 2018 and has held it in 13 quarters since. 50 funds tracked by Wall St. Rank hold SPRO as of Q1 2026.

  • Two Sigma Investments held 885,631 shares of Spero Therapeutics worth $2.07M as of Q1 2026.
  • Two Sigma Investments bought 513,061 Spero Therapeutics shares in Q1 2026, an estimated $1.22M.
  • Spero Therapeutics made up ﹤0.01% of Two Sigma Investments's portfolio in Q1 2026, its #2732 holding.
  • Two Sigma Investments first reported a position in Spero Therapeutics in Q4 2018 and has held it in 13 quarters since.
  • 50 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.